Elanco Animal Health Files 8-K on Exit Costs

TL;DR

Elanco 8-K filed: Exit/disposal costs and Reg FD disclosures as of Dec 5, 2025.

AI Summary

Elanco Animal Health Incorporated filed an 8-K on December 9, 2025, reporting on cost associated with exit or disposal activities and Regulation FD disclosures as of December 5, 2025. The filing details financial statements and exhibits related to these activities.

Why It Matters

This filing indicates Elanco is undergoing restructuring or divesting certain assets, which could impact its future financial performance and strategic direction.

Risk Assessment

Risk Level: medium — Disposal activities can signal financial strain or strategic shifts that may carry inherent risks.

Key Players & Entities

• Elanco Animal Health Incorporated (company) — Registrant
• December 5, 2025 (date) — Date of Earliest Event Reported
• December 9, 2025 (date) — Filing Date
• 450 Elanco Circle Indianapolis, Indiana 46221 (address) — Principal executive offices

FAQ

From the Filing

0001104659-25-119486.txt : 20251209 0001104659-25-119486.hdr.sgml : 20251209 20251209074537 ACCESSION NUMBER: 0001104659-25-119486 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20251205 ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20251209 DATE AS OF CHANGE: 20251209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 251557643 BUSINESS ADDRESS: STREET 1: 450 ELANCO CIRCLE CITY: INDIANAPOLIS STATE: IN ZIP: 46221 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 450 ELANCO CIRCLE CITY: INDIANAPOLIS STATE: IN ZIP: 46221 8-K 1 tm2533048d1_8k.htm FORM 8-K false 0001739104 Elanco Animal Health Inc 0001739104 2025-12-05 2025-12-05 0001739104 us-gaap:CommonStockMember 2025-12-05 2025-12-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D. C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of Earliest Event Reported): December 5, 2025   Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)   Indiana   001-38661   82-5497352 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   450 Elanco Circle Indianapolis , Indiana (Address of principal executive offices)   46221 (Zip Code)   Registrant’s telephone number, including area code: ( 877 ) 352-6261   Not Applicable (Former Name or Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, no par value   ELAN   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   ¨   Emerging growth company   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 2.05 Costs Associated with Exit or Disposal Activities.   On December 5, 2025, the Board of Directors of Elanco Animal Health Incorporated (the “Company”) authorized a restructuring plan with respect to its workforce (the “Restructuring Plan”) to support margin expansion, optimize the Company’s footprint, and further invest in innovation. The Restructuring Plan will result in a global headcount reduction of approximately 300 employees, plus an appro